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Abstract
Purpose: The eukaryotic translation initiation factor eIF4E is part of the eIF4Fprotein complex, which includes, in addition to eIF4E, eIF4G (a scaffolding protein)and eIF4A (an ATP-dependent RNA helicase). The eukaryotic translation initiationfactor eIF4E is a potent oncogene elevated in many cancers including leukemias.
Methods: In this study, the expression level of eIF4E gene was analyzed in 20normal healthy controls and 64 patients with de novo acute leukemia (33 Acutemyeloid leukemia (AML) and 31 Acute lymphoblastic leukemia (ALL)) using areal-time quantitative reverse-transcriptase polymerase chain reaction (RTQ-PCR)to investigate a possible relation, association or correlation with the clinicalfeatures at diagnosis, such as age, gender, lineage, hemoglobin (Hb), total leucocyticcount (TLC), platelet	count	and	bone	marrow	(BM)	blast	cell	infiltration	as	well	as	its	 effect	 on	 patients̒	 outcome.	 Results: Comparing AML and ALL patients asregards their clinical and laboratory data showed no statistical significance for TLCand hemoglobin (p = 0.838 and 0.920. respectively) but was of statisticallysignificant difference for platelets (p = 0.022) and bone marrow blasts percentage(p = 0.007). Comparison between the 2 groups as regards eIF4E level was of nostatistically significant difference, p-value being (p = 0.257) but there wasstatistically significant difference between eIF4E expression level in AML/Control(p = 0.002) and ALL/Controls (p = 0.025). Analysis of overall survival (OS) time anddisease free survival (DFS) in each group and its relation to eIF4E gene showed nostatistical significance (p = 0.843 and 0.310, respectively) in AML group and (p =0.971 and no p-value for DFS in ALL as all cases remained alive except for one casewhile 3 cases were relapsed) in ALL group. Correlation studies showed nosignificant correlation between AML group and eIF4E gene level as regards age,TLC, hemoglobin and platelets (r = -0.064, p = 0.722; r = 0.062, p = 0.732; r = 0.068,
p = 0.712; and r = -0.318, p = 0.071) respectively, while there was significantpositive moderate correlation on comparing bone marrow blast% and eIF4E genelevel (r = 0.545 and p = 0.001). There was no significant correlation between ALLgroup and Eif4e gene level as regards age, TLC, hemoglobin, platelets and bonemarrow blasts% (r = -0.214, p = 0.248; r = 0.175, p = 0.347; r = -0.056, p = 0.766; r =-0.072, p = 0.700; and r = -0.0004, p = 0.983) respectively. Conclusion: eIF4E wasfound to be elevated in acute leukemia patients in relation to normal controls andits levels were more in myeloid than lymphoid leukemia and positively correlatedwith the blast percentage in AML thus its level may contribute to leukemogenesis.eIF4E levels and translation initiation may be an attractive target for anticancertherapeutics.
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1. IntroductionThe eukaryotic translation initiation factor 4E (eIF4E) isfrequently overexpressed in human cancers in relationto disease progression and drives cellulartransformation, metastatic progression andtumorigenesis in experimental models. Enhanced eIF4Efunction results from eIF4E overexpression and/oractivation of the ras and phosphatidylinositol3-kinase/AKT pathways and selectively increases thetranslation of key mRNAs involved in tumor growth,angiogenesis, and cell survival. Targeting eIF4E forinhibition may provide an attractive therapy for manydifferent tumor types.1eIF4E overexpression has been demonstrated in humantumors and has been related to disease progression.Overexpression of eIF4E in experimental modelschanges cellular morphology, enhances proliferation andinduces cellular transformation, tumorigenesis andmetastasis. On the contrary, blocking eIF4E function byexpression of antisense RNA, or overexpression of theinhibitory eIF4E binding proteins (4E-BPs), inhibitscellular transformation, tumor growth, invasiveness andmetastasis.2eIF4E is a well-established proto-oncogene; whoseexpression and activation is associated withtransformation and tumorigenesis. MnKs (MAP (mitogenactivated protein) kinase interacting kinases)phosphorylate Eif4E at a single site. Thisphosphorylation is implicated in cell transformation,tumorigenesis and tumor progression.3Abnormal translation of mRNAs frequently occurringduring carcinogenesis is among the mechanisms that canaffect the expression of proteins involved in tumordevelopment and progression. eIF4E is a key regulatorof translation of many cancer-related transcripts and itsexpression is altered in various cancers and wasassociated with worse survival.4Regulation of mRNA translation is an importantregulatory step in gene expression. During embryonicdevelopment, mRNA translation is tightly regulated toproduce the protein at the right place and time. eIF4E isa major target for the regulation of cap-dependenttranslation, that plays a key role during embryogenesisincluding gametogenesis, fertilization and establishmentof embryonic axes.5Protein synthesis is a complex, tightly regulated processin eukaryotic cells and its deregulation is a hallmark ofmany cancers. Translational control occurs primarily atthe rate-limiting initiation step, where ribosomalsubunits are recruited to template mRNAs through theconcerted action of several eukaryotic initiation factors(eIFs). One factor that interacts with both the mRNA andribosomes, and appears limiting for translation is eIF4F,a complex composed of the cap-binding protein, eIF4E;
the scaffold protein, eIF4G; and the ATP-dependentDEAD-box helicase, eIF4A.6Many studies aimed to compare the expression level ofeIF4E in patients with leukemia and normal controls,and to explore its role in leukemogenesis. The mRNAand protein expressions of eIF4E were detected byQT-PCR and the absolute expression level of eIF4EmRNA and its protein expression were up regulated inmost leukemia patients, which may play an importantrole in leukemogenesis, so the eIF4E may be a promisingtarget for leukemia therapy and eIF4E-targeted therapymay be an option.7This study aimed to investigate the expression level ofeIF4E gene in acute leukemia patients using QRT-PCR toelucidate any possible relation or correlation withpatients clinical and laboratory data and its effect onpatients′ outcome.
2. Methods and Materials
2.1. Patients and controls seriesSixty-four Egyptian patients with acute leukemia wereincluded in this study. Patients were recruited fromBeni-suef University hospital, Health Insurance hospital,Beni-Suef governorate and Cairo university hospitals,Egypt between December 2013 and December 2014.Informed consent was taken from all contributors priorto their inclusion in the study. All work was performedin accordance with the ethical standards of the 2008declaration of Helsinki.8Patients were 33 acute myeloid leukemia (AML) and 31acute lymphoblastic leukemia (ALL), 39 male and 25females. All the patients were newly diagnosed and didnot receive any treatment.Twenty age and sex matched healthy individuals withnormal laboratory findings were included as a controlgroup. They were 9 male and 11 females. Their ageranged between 10-45 years with a mean of 23.2±12.4years. Diagnosis of acute leukemia was based on (1)morphologic findings from Giemsa stained smears ofbone marrow (BM) aspirates, (2) cytochemical stainscriteria such as negativity for myeloperoxidase (MPO)and Sudan Black B (SBB) in cases of acute lymphoblasticleukemia [ALL] or their positivity in cases of acutemyeloid leukemia [AML] and positivity for acidphosphatase in T-cell acute lymphoblastic leukemia[T-ALL] and (3) immunophenotyping criteria asCD10+/− CD19+, CD20+, CD22+ for B-ALL, CD2+/−,CD3+, CD5+/−, CD7+ for T-ALL, and positivity of CD13and CD33 for AML cases. A complete blood count and adifferential count including blast cell percentage weredone for all patients. Peripheral blood (PB) samples andbone marrow (BM) aspiration samples were collected atdiagnosis from the 64 Egyptian acute leukemia patients,
Volume 4 • Number 3 • 2016                                               International Journal of Cancer Therapy and Oncology 3
www.ijcto.org
© Hammam et al. ISSN 2330-4049
while peripheral blood samples were obtained from thecontrol group.eIF4E gene was analyzed in patients and controls usingreal-time quantitative reverse transcriptase polymerasechain reaction (RTQ-PCR) to study mRNA expressionlevels.
2.2. RNA isolation and real-time quantitative
RT-PCR for eIF4EPB and BM mononuclear cells (MNCS) were isolated atdiagnosis by Ficoll density gradient centrifugation. TotalRNA was extracted from MNCs using a QIAamp RNABlood Kit (Qiagen, Germany) according tomanufacturer’s instructions. Complementary DNA(cDNA) was synthesized using (dt) 15-mer primer bySuperscript III Reverse Transcriptase and stored at-20◦C till use.The mRNA expression levels of eIF4E gene and GAPDH(endogenous control) were measured by quantitativeRT-PCR using an ABI PRISM 7000 Sequence DetectorSystem (Applied Biosystems, Foster City, CA). Thequantitative RT-PCR amplification was performed usingthe predeveloped assays-on-demand Gene ExpressionSet for the eIF4E (no 4532182, ID: NCT 00559091) andTaqMan GAPDH control reagents (Applied Biosystems)with the TaqMan Universal PCR Master Mix (AppliedBiosystems).All reactions were performed in duplicate using 20 µlsamples containing 50 ng cDNA. The reaction protocolused involved heating for 2 min at 50◦C and 10 min at95◦C, followed by 40 cycles of amplification (15 s at 95
◦C and 1 min at 60◦C). Analysis was performed using ABIPRISM 7000 Sequence Detection Software (AppliedBiosystems).The expression levels of eIF4E gene in tested sampleswere expressed in the form of CT (cycle threshold) level;then normalized copy number (relative quantitation)was calculated using the ∆∆CT equation as follows: ∆∆CT= ∆CT of case - ∆CT of control, then the normalized copynumber (relative quantitation) = 2−∆∆CT. A negativecontrol without template was included in eachexperiment.Expression level of eIF4E was correlated with theclinical and laboratory features of the studied patients atdiagnosis including: age, sex, organomegaly,lymphadenopathy, total leucocytic count (TLC),hemoglobin (Hb), platelet count, lineage and blast cellpercentage at time of diagnosis, as well as the overallsurvival, disease free survival and complete remissionrate after treatment.
2.3. Treatment of AML patientsAML patients were treated according to Department ofOncology, Cairo University. All patients received
induction chemotherapy 7-3 protocol consisted of acourse of 12mg/m² novantrone on day 1,3 and 5; Ara-C100mg/m² continuously every 12 hours from day1through 7.If the patient did not enter into remission,this protocol was repeated. If no or minimal response,patients were shifted to high dose chemotherapy.Patients who entered into remission received 4 coursesof high dose Ara C as consolidation. This was Ara-C2g/m² on 2 hours infusion every 12 hours day 1, 3 and5.9
2.4. Treatment of ALL patients:ALL patients were treated according to the treatmentprotocol adopted from the total therapy study XV forstandard/high risk ALL of St. Jude Children′s ResearchHospital (SJCRH). It included 6 weeks of induction, 8weeks of consolidation, and continuation therapy of 120weeks for girls and 146 for boys.10
2.5. Assessment of the response to induction
chemotherapyBy the end of induction therapy, complete remission(CR) status was defined as a normocellular bone marrow(BM) containing less than 5% blasts and showingevidence of normal maturation of other marrowelements. Peripheral blood regeneration was not arequirement, but 97% of cases defined as CR achieved aneutrophil count of 1×10⁹/L and a platelet count of100×10⁹/L.Remission failures were classified as either partialremission (defined as 5-15% blasts or <5% blasts but ahypocellular BM), resistant disease (RD) >15% blasts inthe BM, or induction death (ID) (i.e: related to treatmentor hypoplasia). Overall survival (OS) end points weremeasured from the date of diagnosis to death or lastfollow up.11
2.6. Statistical methodsData was analyzed using IBM SPSS advanced statisticsversion 20 (SPSS Inc., Chicago, IL). Numerical data wereexpressed as mean and standard deviation or medianand range as appropriate. Qualitative data wereexpressed as frequency and percentage. For notnormally distributed quantitative data, comparisonbetween two groups was done using Mann-Whitney test(non-parametric t-test). Pearson and Spearman-rhomethods were used to test correlation between gene andnumerical variables. Survival analysis was done usingKaplan-Meier method and comparison between twosurvival curves was done using log-rank test. Relation ofsurvival with the gene was done using Cox-regressionmethod. All tests were two-tailed. A p-value < 0.05 wasconsidered significant.
3. ResultsThe present study was conducted on 64 acute leukemiapatients (33 AML and 31 ALL), clinical and laboratory
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characteristics of which were presented in Table 1.Twenty normal healthy volunteers age and sex matchedserved as a control group.They were 39 male patients (21 AML&18 ALL) and 25female patients (12 AML &13 ALL), while controls were9 males and 11 females. The AML cases were classifiedaccording to FAB classification : 2 case M0 (6%), 8M1(24.2%), 15 M2 (45.5%), 4 M3(12.1%), 1 M4(3%),1M5(3%), 2 M7 (6.1%) while the ALL cases were 3 casespre B (9.7%), 1 pro B (3.2%), 1 C ALL (3.2%), 3 TALL
(9.7%), 7 L1 (22.6%), 14 L2 (45.2%), 2 early T (6.5%).AML and ALL patients characteristics in comparison toeif4 gene expression levels and its significance werepresented in Tables 2 and 3, respectively.Comparing AML and ALL patients as regards theirclinical and laboratory data showed no statisticalsignificance for TLC and hemoglobin (p-0.838 and0.920) respectively, but was of statistically significantdifference for platelets (p = 0.022) and bone marrowblasts percentage (p = 0.007).
Table 1: Clinical and Laboratory data of the AML &ALL patients.AMLn = 33 ALLn = 31Age(years)mean±SDmedianrange 31.4±15.5358-66 17.6±17.7127.0-64Sex (n,%)MaleFemale 21 (63.6%)12 (36.4%) 18 (58.1%)13 (41.9%)TLCX10³mean±SDmedianrange 33.4±32,924.41.0-119.0 44.2±52.322.91.3-213.0Haemoglobin(gm/dl)mean±SDmedianrange 7.7±2.47.43.5-13.9 7.4±2.67.32.3-14.0PlateletsX 10³mean±SDmedianrange 43.8±482.02-244 75.9±65.362.06.0-296.0B.M Blast (%)mean±SDmedianrange 72.18±29.79015-98 79.6±25.99220-100CSF (%)Negativepositive 33(100%)0(0%) 26(83.9%)5(16.1%)Hepatomegaly (n%)NegativePositive 18(54.5%)15(45.5%) 13(41.9%)18(58.1%)Splenomegaly (n%)NegativePositive 13(39.4%)20(60.6%) 5(16.1%)26(83.9%)LymphadenopathyNegativePositive 19(57.6%)14(42.4%) 5(16.1%)26(83.9%)ResponseCR (n %)No CR (n %) 18 (54.5%)15 (45.5%) 30(96.8%)1(3.2%)OSDFS 24(72.7%)18(54.4%) 30(96.8%)27(87.1%)Eif4e levelmean±SDmedianrange 74.407±195.1030.2060.003-930.847 27.741±96.7390.00320.-504.951
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Table 2: AML Patient characteristics and eif4e expression levels in different clinical groups.
p-valueRangeEif4e level(mean ± SD)No. ofpatientsGroup *0.0160.005-930.840.003-57.900113.208±237.4976.506±16.6372112Sex (n,)MaleFemale *<0.0010.003-0.4090.022-930.840.064±0.129111.579±231.6501122B.M Blast (%)<90≥90 0.3430.004-930.840.003-525.48102.129±234.49741.141±134.7981815Hepatomegaly (n%)NegativePositive 0.7300.004-930.840.003-525.4889.490±255.77664.603±150.1141320splenomegaly (n%)NegativePositive 0.4830.004-133.060.003-930.8416.328±34.298153.229±283.6361914LymphadenopathyNegativePositive *p-values are significant <0.05
Table 3: ALL Patient characteristics and eif4e expression levels in different clinical groups.
p-valueRangeEif4e level(mean ± SD)No. ofpatientsGroup 0.6220.00-166.5720.001-504.9519.255±50.25939.490±139.8571813Sex (n,)MaleFemale
0.0100.00-1.0430.003-504.950.137±0.36637.342± 111.3011823B.M Blast (%)<90≥90 0.2800.00-166.5720.007-504.9513.086±42.438103.947±224.225265CSF (%)Negativepositive 0.2420.00-6.1950.00-504.9510.825±1.79747.180±124.7341318Hepatomegaly (n%)NegativePositive 0.0710.033-504.950.00-166.572102.730±229.86113.320±42.416526splenomegaly (n%)NegativePositive 0.1030.033-504.950.00-166.572102.446±225.02013.374±42.401526LymphadenopathyNegativePositive *p-values are significant <0.05
Table 4: Eif4e gene expression levels in the 3 studied groups and statistical comparison between them.Eif4egenelevel ControlN=20 AMLn=33 ALLn=31 p-ValueLevel (RQ)mean±SDmedianrange 0.0984±0.2220.01010.01-1.0 74.407±195.1030.2060.003-930.847 27.741±96.7390.00320.-504.951 P1=0.257*P2=0.002*P3=0.025*p-values are significant <0.05
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Table 5: Relationship between patient outcome and Eif4e gene expression.Group AMLn=33 ALLn=31 p-valueOverallsurvival (event) 24(72.7%) 30(96.8%) P1 =0.971P2=0.843Disease freesurvival (event) 18(54.4%) 27(87.1%) P3=0.310P4= no p-value*p-values are significant <0.05P1: Eif4e gene/OS in AMLP2: Eif4e gene/OS in ALLP3: Eif4e gene/DFS in AMLP4: Eif4e gene/DFS in ALL (no p-value as all cases remain free except the case who died early and 3 relapsed cases)
Figure 1: Correlation between Eif4e expression level and bone marrow blasts in AML patients.Comparison between the 2 groups as regards Eif4e levelwas of no statistically significant difference, p-valuebeing (p = 0.257) but there was statistically significantdifference between Eif4e expression level inAML/Control (p = 0.002), ALL/Controls (p = 0.025)(Table 4). Response to treatment of AML cases showedthat post induction chemotherapy 18/33 (54.5%)entered complete remission (CR) while 14/33 (45.5%)did not enter CR overall survival (OS) time was of mean11.43 ± 7.83 months, with median 13.03 and range(0.66-22.86) months, While the disease free survival(DFS) time was of mean 11.01 ± 7.83 months withmedian 13.09 and range (0.3-22.34) months in AML.While response to treatment of ALL cases showed that30/31 (96.8%) entered in CR and only 1/31 (3.2%) didnot enter CR. Overall survival (OS) time was of mean23.47 ± 9.09 months, with median 23.06 and range(3.39-52.37) months. While the disease free survival(DFS) time was of mean 23.90±8.50 months withmedian 24.29 and range (9.38-51.74) months in ALL.
Also analysis of OS and DFS in each group and itsrelation to Eif4e gene showed no statistical significance(p = 0.843 and 0.310, respectively) in AML group and (p= 0.971 and no p-value for DFS in ALL as all casesremained alive except for one case who died and 3relapsed cases) in ALL group (Table 5).Correlation studies showed no significant correlationbetween AML group and Eif4e gene level as regards age,TLC, hemoglobin and platelets (r = -0.064 p=0.722, r =0.062 p = 0.732, r = 0.068 p = 0.712 and r = -0.318 p =0.071) respectively, while there was significant positivemoderate correlation on comparing bone marrowblast% and Eif4egene level (r = 0.545 and p = 0.001)(Figure 1 )There was no significant correlation between ALL groupand Eif4e gene level as regards age, TLC, hemoglobin,platelets and bone marrow blasts% (r = -0.214 p=0.248,r = 0.175 p = 0.347, r = -0.056 p = 0.766, r= -0.072 p =0.700 and r=-0.0004 p= 0.983) respectively.
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4. DiscussionThe eukaryotic translation initiation factor 4E (eIF4E) isa potent oncogene which is elevated in about 30% ofhuman cancers including the M4 and M5 subtypes ofAcute Myelogenous Leukemia (AML) and in blast crisis,but not chronic phase of chronic myeloidleukemia(CML).12 eIF4E overexpression leads toincreased proliferation, oncogenic transformation,evasion of apoptosis, tumor invasion andmetastases.12–14 eIF4E interacts with themethyl-7-guanosine cap moiety on the 5’ end of mRNAsand via this activity plays a central role in cap dependenttranslation and in nucleo-cytoplasmic export of a subsetof transcripts encoding proteins involved in cellulargrowth, survival and transformation such as Cyclin D1,vascular endothelial grouth factor (VEGF) , Mcl1, c-myc,and Pim1.15 Both the export and translation activities ofeIF4E contribute to its transformation potential.16Depletion of eIF4E in cancer cells using anti-senseoligonucleotides, siRNA or pharmacological inhibitorsleads to cell cycle arrest and decreased tumorigenicity
17–20 eIF4E is a downstream eukaryotic translationinitiation factor of the PI3K/AKT/mTOR pathway, and ishighly elevated in the M4 and M5 subset of AML at boththe RNA and protein levels.21 eIF4E acts as both a keytranslation factor and as a promoter ofnucleocytoplasmic transport of specific transcripts , itstransformation capacity in vivo is attributed to its role intranslation initiation in the cytoplasm.22In the present study the expression of eIF4E mRNA wasmeasured by QRT-PCR in 64 denovo AL patients incomparison with 20 healthy control subjects, to find apossible relation or correlation with the clinical andlaboratory features of AL patients at diagnosis, such asage, gender, lineage (AML or ALL), Hb, TLC, plateletscount and bone marrow blast cell infiltration as well aspatients outcome.Comparing AML and ALL patients as regards theirclinical and laboratory data showed no statisticalsignificance for TLC and hemoglobin with p value being(0.838 and0.920) respectively, but was of statisticallysignificant difference for platelets (p = 0.022) and bonemarrow blasts (p = 0.007).Comparison between the 2 groups as regards Eif4e levelwas of no statistically significant difference, p-valuebeing (p = 0.257) but there was statistically significantdifference between Eif4e expression level inAML/Control (p = 0.002), ALL/Controls (p = 0.025)(Table 4). Also analysis of OS and DFS in each group andits relation to Eif4e gene showed no statisticalsignificance (p = 0.843 and 0.310) respectively in AMLgroup and (p = 0.971) in ALL group (Table 5).Correlation studies showed no significant correlationbetween AML group and Eif4e gene level as regards age,
TLC, hemoglobin and platelets (p = 0.722, 0.732, 0.712,and 0.071, respectively), while there was significantpositive moderate correlation on comparing bonemarrow blast% and Eif4egene level (r = 0.545 and p =0.001) ( Figure 1).There was no significant correlation between ALL groupand Eif4e gene level as regards age, TLC, hemoglobin,platelets and bone marrow blasts % (p = 0.248, 0.347,0.766, 0.700, and 0.983, respectively).In accordance with our study; Zhu et al.7 compared theexpression level of eIF4E in patients with leukemia andnormal controls, and explored its role inleukemogenesis. They found that compared with normalcontrols, the absolute expression levels of eIF4E mRNAincreased in patients with AML, ALL and CML in blasticphase (p < 0.05), but had no significant change betweengroups of CML in chronic and accelerated phasealthough some increasing in group of CML in acceleratedphase. They found that the relative expression level ofeIF4E mRNA had no significant change in AML, ALL, CMLgroups except the two subtypes of leukemia M4 and M5.Furthermore, they found that the protein expressionlevel in group of CML in accelerated phase and blasticphase and all acute leukemia patients including AML andALL were higher than that in normal controls (P < 0.05).In our study we couldn’t reach the same outcomeconcerning M4 and M5 because we only had 1 case ofeach FAB subgroup.Jiang et al.23 detected in their study the expression levelof eIF4E gene in patients with non-treated, remissionand non-remission/relapse acute myeloid leukemia(AML), and other non-malignant haematologic diseasesto analyze and reveal the relationship of eIF4E geneexpression with AML progression using SYBR Green IRT-PCR. The results showed that the eIF4E expressionlevel in patients with non-treated andnon-remitted/relapsed AML was significantly higherthan that in patients with remission (P < 0.01) andnon-malignant hematologic diseases (P < 0.01). Therewas no difference between latter two group patients,even though the expression level of eIF4E gene inpatients with M4 and M5 was higher. As compared withnon-malignant hematologic diseases, the expressionlevel of eIF4E gene of patients with remission patientsshowed no significant difference. They concluded thatthe over-expression of eIF4E gene has been found inpatients with AML, and its level obviously decreasesalong with remission of disease, thus they concludedthat eIF4E gene may be an indicator for diseaseprogression.This was in agreement with our study as we showed thatAML cases expressed higher levels of the gene thannormal controls and this was significantly positivelycorrelated to the blast percentage. We did not
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demonstrate difference in levels of gene expression ofFAB subtypes M4 and M5 and this probably is due to thesmall number of cases of these subtypes (1 case each).In their study; Ivan, et al.22 demonstrated that elevatedeIF4E blocks monocytic and granulocytic differentiation.Their subsequent mutagenesis studies indicate that thisblock is a result of dysregulated eIF4E-dependent mRNAtransport. These studies indicate that the RNA transportfunction of eIF4E could contribute to leukemogenesis.They extended their studies to provide evidence that thenuclear transport function of eIF4E contributes tohuman malignancy, specifically in a subset of acute andchronic myelogenous leukemia patients. They observedan increase in eIF4E-dependent cyclin D1 mRNAtransport and a concomitant increase in cyclin D1protein levels. Thus, their findings indicate that thisnuclear function of eIF4E can contribute toleukemogenesis by promoting growth and by blockingdifferentiation, which was in agreement with ourfindings.
5. ConclusionIn conclusion, eIF4E was found to be elevated in acuteleukemia patients compare to normal controls and itslevels were more in myeloid than lymphoid leukemiaand positively correlated with the blast percentage inAML thus its level may contribute to leukemogenesis.Eif4e levels and translation initiation may be anattractive target for anticancer therapeutics. Thoughthere are different treatment protocols for ALL and AMLbetween adult and Pediatric age groups, yet in our studywe tried to assess the clinical significance of eIF4E inALL and AML regardless the different biologic behaviorin both groups. Future studies correlating different drugregimens with the gene level may be of great benefit.
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